EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Multidrug-resistant Tuberculosis Treatment Outcomes: High Success Rates of The BPaL Regimen Across Diverse Resistance Profiles In Indonesia

Heidy Agustina, Abdullah Antaria, Erlina Burhan, Fathiyah Isbaniyah, RR Diah Handayani, Ratnawati Ratnawati

Respiratory Science · 26.10.2026 · 7 (1) · 1-7

DOI: 10.36497/respirsci.v7i1.246 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Respiratory Science, online erschienen am 26.10.2026. Verfasst von Heidy Agustina und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Multidrug-resistant tuberculosis (MDR-TB) remains a public health challenge in Indonesia, with 29,600 annual cases and conventional regimens achieving only 59% success. The Bedaquiline-Pretomanid-Linezolid (BPaL) regimen, which is a six-month all-oral treatment endorsed by the World Health Organization (WHO), offers a potential solution. Yet, real-world evidence in high-burden settings is limited. This study aims to assess the clinical efficacy and safety of the BPaL regimen across MDR-TB profiles in Indonesia.

Method

This retrospective cohort study conducted at Persahabatan Hospital, Jakarta (2021–2024), included 84 patients receiving the BPaL regimen and diagnosed via GeneXpert MTB/RIF or culture. Differences in treatment outcomes based on drug-resistance profiles were assessed using Fisher's exact test. Exploratory comparisons with historical-control success rates were performed using two-sided exact binomial tests.

Results

Treatment success was achieved in 77.4% of all patients. Among patients with drug-resistance profiles, success rates were 84.2% for RR-TB, 75.0% for MDR-TB, and 75.0% for pre-XDR-TB, with no significant between-profile difference (P=0.596). Overall success was higher than the 59% historical-control benchmark (P

Zitieren

APA

Agustina, H., Antaria, A., Burhan, E., Isbaniyah, F., Handayani, R. D., & Ratnawati, R. (2026). Multidrug-resistant Tuberculosis Treatment Outcomes: High Success Rates of The BPaL Regimen Across Diverse Resistance Profiles In Indonesia. Respiratory Science, 7(1), 1-7. https://doi.org/10.36497/respirsci.v7i1.246

Vancouver

Agustina H, Antaria A, Burhan E, Isbaniyah F, Handayani RD, Ratnawati R. Multidrug-resistant Tuberculosis Treatment Outcomes: High Success Rates of The BPaL Regimen Across Diverse Resistance Profiles In Indonesia. Respiratory Science. 2026;7(1):1-7. doi:10.36497/respirsci.v7i1.246

BibTeX
@article{Agustina2026,
  author = {Agustina, Heidy and Antaria, Abdullah and Burhan, Erlina and Isbaniyah, Fathiyah and Handayani, RR Diah and Ratnawati, Ratnawati},
  title = {Multidrug-resistant Tuberculosis Treatment Outcomes: High Success Rates of The BPaL Regimen Across Diverse Resistance Profiles In Indonesia},
  journal = {Respiratory Science},
  year = {2026},
  volume = {7},
  number = {1},
  pages = {1--7},
  doi = {10.36497/respirsci.v7i1.246}
}
Kostenlos starten →